Zemplar and Urinary tract infection - a phase IV clinical study of FDA data

Summary:

Urinary tract infection is reported as a side effect among people who take Zemplar (paricalcitol), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Lasix, and have Hyperparathyroidism secondary.

The phase IV clinical study analyzes which people have Urinary tract infection when taking Zemplar. It is created by eHealthMe based on reports of 15,456 people who have side effects when taking Zemplar from the FDA, and is updated regularly.

What is Zemplar?

Zemplar has active ingredients of paricalcitol. It is often used in kidney disease. eHealthMe is studying from 15,494 Zemplar users. Check the latest studies of Zemplar.

What is Urinary tract infection?

Urinary tract infection is found to be associated with 3,014 drugs and 3,957 conditions by eHealthMe. Check the latest studies of Urinary tract infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

15,456 people reported to have side effects when taking Zemplar.
Among them, 144 people (0.93%) have Urinary tract infection.

Could Zemplar cause Urinary tract infection?

Among these 144 people:

How long have people been on Zemplar when they have Urinary tract infection? *

Click here to view more results

What is the gender of people who have Urinary tract infection when taking Zemplar? *

Click here to view

What is the age of people who have Urinary tract infection when taking Zemplar? *

Click here to view more results

* Approximation only. Some reports may have incomplete information.

Do you take Zemplar and have Urinary tract infection?

- Check whether Urinary tract infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zemplar:

Zemplar (15,494 reports)

Urinary tract infection treatments and more:

Urinary tract infection (281,662 reports)

How severe was Urinary tract infection and when was it recovered:

Urinary tract infection in Zemplar

Expand to all the drugs that have ingredients of paricalcitol:

Urinary tract infection and drugs with ingredients of paricalcitol (158 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zemplar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urinary tract infection:

Urinary tract infection (3,014 drugs)

Browse all the conditions that are associated with Urinary tract infection:

Urinary tract infection (3,957 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on paricalcitol (the active ingredients of Zemplar) and Zemplar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.